Khorana score for cancer-associated VTE
VTE risk in ambulatory patients starting chemotherapy.
Inputs
CompleteCancer site
Platelets 350 × 10³/µL or higher
Hemoglobin below 10 g/dL or using an ESA
WBC above 11 × 10³/µL
BMI 35 or higher
Worked calculation
Your values are highlighted.
- Points
When to use
- Ambulatory cancer patients starting systemic therapy.
Pearls and pitfalls
- ASCO: offer apixaban, rivaroxaban, or LMWH prophylaxis for score 2 or higher if bleeding risk allows.
Why use
The guideline-endorsed cancer VTE model.
| Criterion | Points |
|---|---|
| Cancer site: Other | 0 |
| Lung, lymphoma, gynecologic, bladder, or testicular | +1 |
| Stomach or pancreas | +2 |
| Platelets 350 × 10³/µL or higher | +1 |
| Hemoglobin below 10 g/dL or using an ESA | +1 |
| WBC above 11 × 10³/µL | +1 |
| BMI 35 or higher | +1 |